Pfizer Beats 1q Profit Forecasts, But Sales Dip Misses Views

Pfizer beat Wall Street expectations for first-quarter profit thanks to reduced spending on operations and legal costs, along with strong sales of key new drugs and longtime blockbuster pain treatment Lyrica. [...] the top U.S. drugmaker had a disappointing revenue dip of 1 percent as competition hurt overseas sales of the immune disorder drug Enbrel. Pfizer continued its aggressive pursuit of companies that can boost its sales and its pipeline of future drugs, completing three significant deals — two purchases and a sale — since January of 2016.

Topics:  wall street   lyrica   u.s    enbrel   pfizer   january   profit   sales   dip   drugs   

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News